Foghorn Therapeutics Inc. (FHTX) could be a solid choice for investors given its recent upgrade to a Zacks Rank #1 (Strong Buy). This rating change essentially reflects an upward trend in earnings ...

In a report released yesterday, Jonathan Koh from UOB Kay Hian maintained a Buy rating on Digital Core REIT (DCRU – Research Report), with a ...

AppLovin, Silvercorp Metals and Powell Industries have been selected as the top picks with a high net income ratio.

ProAssurance faces challenges in medical malpractice insurance, but shows improvement in net income. See why I rate PRA stock ...

Growth stocks are equity shares likely to outperform their peers and the broader market. Here's a list of stocks that contain investment potential to beef up your portfolio.

Needham analyst Ami Fadia maintained a Buy rating on Axsome Therapeutics (AXSM – Research Report) today and set a price target of $133.00.Don't ...

LifeVantage's new MindBody GLP-1 System is riding the coattails of GLP-1 weight loss drugs. See why I rate LFVN stock as a ...

Trump Media has for the most part been a speculative investment. The stock could often be viewed as a gauge as to how likely ...

XRP price shows strong potential for a rally to $100, but this AI altcoin is a better buy with 45,000% returns expected in ...